199 results
8-K
EX-99.1
SVRA
Savara Inc
5 Jan 24
Regulation FD Disclosure
8:00am
expansion opportunities As a novel inhaled biologic, molgramostim has: ▪ 12-year biologic exclusivity in U.S. ▪ Potential for a long-term, durable revenue … patient at baseline (week 0) after treatment (week 24) From IMPALA trial 8 © Savara Inc. All Rights Reserved.
aPAP is a Rare, Long-Term, Chronic
8-K
EX-1.1
yljz9y
13 Jul 23
Savara Announces Pricing of $80 Million Underwritten Offering of Common
5:18pm
424B5
f95y1s
13 Jul 23
Prospectus supplement for primary offering
5:17pm
8-K
EX-99.1
6pm8crpi3zdx4qjy5n2
8 Jun 23
Regulation FD Disclosure
4:20pm
S-8
EX-4.1
nn5 3bkic
30 Mar 23
Registration of securities for employees
5:10pm
8-K
EX-99.1
hp4e9m
10 Jan 22
Regulation FD Disclosure
8:02am